AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38402096 — intervention group
Group type: EXPERIMENTAL
Intervention: PRONEtect Education Hub (digital platform)
Number of subjects: 80
Study 38402096 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture (control group)
Number of subjects: 80
Study 38402173 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy
Number of subjects: 0
Study 38402173 — intervention group
Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 0
Study 38402303 — intervention group
Group type: EXPERIMENTAL
Intervention: FluMos-v1 (mosaic influenza nanoparticle vaccine)
Number of subjects: 0
Study 38402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Orforglipron (LY3502970) 3 mg (study A)
Number of subjects: 46
Study 38402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Orforglipron (LY3502970) 16 mg (study B)
Number of subjects: 46
Study 38402353 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute (75% sodium chloride and 25% potassium chloride by mass)
Number of subjects: 20995
Study 38402353 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 20995
Study 38402361 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive ICU treatment (invasive ventilation for > 24 hours, continuous renal replacement therapy, or both)
Number of subjects: 0
Study 38402361 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing severity of acute illness
Number of subjects: 0
Study 38402373 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 155
Study 38402374 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab QW (0.4 mg/kg weekly)
Number of subjects: 288
Study 38402374 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab Q2W (0.8 mg/kg every other week)
Number of subjects: 288
Study 38402374 — intervention group
Group type: COMPARATOR
Intervention: Real-world physician's choice (RWPC)
Number of subjects: 288
Study 38402467 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib-dexamethasone (Isa-Kd)
Number of subjects: 0
Study 38402467 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib-dexamethasone (Kd)
Number of subjects: 0
Study 38402708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low glycemic index therapy (LGIT)
Number of subjects: 132
Study 38402708 — intervention group
Group type: COMPARATOR
Intervention: Daily low glycemic index therapy (LGIT)
Number of subjects: 132
Study 38402886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg per day)
Number of subjects: 78
Study 38402886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 38402886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 78
Study 38403166 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed voids (morning, afternoon, evening, overnight)
Number of subjects: 441
Study 38403166 — intervention group
Group type: EXPERIMENTAL
Intervention: Single voids (evening)
Number of subjects: 441
Study 38403166 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired voids (afternoon + overnight for sodium; morning + evening for potassium)
Number of subjects: 441
Study 38403166 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple voids (morning + evening + overnight for sodium; morning + afternoon + evening for potassium)
Number of subjects: 441
Study 38403166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size increase
Number of subjects: 441
Study 38403186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) for 15 minutes, twice daily (bid).
Number of subjects: 11
Study 38403186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) without pressure support.
Number of subjects: 11
Study 38403186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) with additional pressure support.
Number of subjects: 11
Study 38403186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS).
Number of subjects: 11
Study 38403186 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 11
Study 38403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide (200-μg dose)
Number of subjects: 0
Study 38403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide
Number of subjects: 0
Study 38403865 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (600 mg intramuscular, 300 mg tixagevimab/300 mg cilgavimab)
Number of subjects: 910
Study 38403865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study 38403887 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including initiation of antiretroviral therapy (ART) during admission, strengths-based case management, and naltrexone
Number of subjects: 225
Study 38403887 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 225
Study 38403887 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 225
Study 38403900 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire-based diagnostic model for malignant gastric lesions
Number of subjects: 17360
Study 38403900 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of the questionnaire-based diagnostic model
Number of subjects: 17360
Study 38403984 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Index (SI)
Number of subjects: 151
Study 38403984 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shock Index (MSI)
Number of subjects: 151
Study 38403984 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Shock Index (DSI)
Number of subjects: 151
Study 38403984 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Indices (SI, MSI, DSI)
Number of subjects: 151
Study 38404145 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 2086
Study 38404145 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2086
Study 38404479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score
Number of subjects: 35
Study 38404479 — intervention group
Group type: COMPARATOR
Intervention: Right hemidiaphragmatic excursion
Number of subjects: 35
Study 38404532 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on oral health
Number of subjects: 172
Study 38404532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 172
Study 38404649 — intervention group
Group type: EXPERIMENTAL
Intervention: TEENS+ family-based lifestyle intervention
Number of subjects: 60
Study 38404673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention for chronic pain
Number of subjects: 811
Study 38404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime diagnoses of anxiety disorders
Number of subjects: 132
Study 38404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 132
Study 38404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a regular gynecologist
Number of subjects: 132
Study 38404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime diagnoses of bipolar disorder
Number of subjects: 132
Study 38404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Past 6-month sexual IPV histories
Number of subjects: 132
Study 38404989 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 4714
Study 38404989 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 4714
Study 38405151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone or modified-release hydrocortisone
Number of subjects: 168
Study 38405151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (lower doses)
Number of subjects: 168
Study 38405151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress dosing
Number of subjects: 168
Study 38405151 — intervention group
Group type: COMPARATOR
Intervention: General USA population
Number of subjects: 168
Study 38405151 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 168
Study 38405158 — intervention group
Group type: EXPERIMENTAL
Intervention: Live multistrain probiotic and absorbent smectite co-supplementation
Number of subjects: 46
Study 38405158 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 46
Study 38405755 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI+SFAS
Number of subjects: 525
Study 38405755 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+SFAS
Number of subjects: 525
Study 38405755 — intervention group
Group type: COMPARATOR
Intervention: Education Control
Number of subjects: 525
Study 38405781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCTs) continued for one more year
Number of subjects: 38
Study 38405781 — intervention group
Group type: COMPARATOR
Intervention: Conditional Cash Transfers (CCTs) discontinued
Number of subjects: 38
Study 38406514 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 304
Study 38406514 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 304
Study 38406813 — intervention group
Group type: EXPERIMENTAL
Intervention: THP regimen (docetaxel 75 mg/m2, trastuzumab biosimilar TQB211 8 mg/kg first cycle, 6 mg/kg maintenance, pertuzumab biosimilar TQB2440 or pertuzumab 840 mg first cycle, 420 mg maintenance)
Number of subjects: 28
Study 38406813 — intervention group
Group type: EXPERIMENTAL
Intervention: THP regimen
Number of subjects: 28
Study 38406848 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural anticoagulation (PPA)
Number of subjects: 2989
Study 38406848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2989
Study 38406850 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 hours of in-home unsupervised game-based motor practice
Number of subjects: 80
Study 38406850 — intervention group
Group type: EXPERIMENTAL
Intervention: <5 hours of motor practice
Number of subjects: 80
Study 38406850 — intervention group
Group type: EXPERIMENTAL
Intervention: >10 hours of motor practice
Number of subjects: 80
Study 38406850 — intervention group
Group type: EXPERIMENTAL
Intervention: >30 hours of motor practice
Number of subjects: 80
Study 38406850 — intervention group
Group type: EXPERIMENTAL
Intervention: game-based motor practice
Number of subjects: 80
Study 38407317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuvusertib (M1774) 180 mg QD (once daily), 2 weeks on/1 week off treatment
Number of subjects: 55
Study 38407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised screenings for swallowing difficulties
Number of subjects: 195
Study 38407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-oral route of medication administration
Number of subjects: 195
Study 38407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of solid medications (SMs)
Number of subjects: 195
Study 38407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gugging Swallowing Screen
Number of subjects: 195
Study 38407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified medication administration before specialist consultation
Number of subjects: 195
Study 38407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of whole SMs administration
Number of subjects: 195
Study 38407394 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 177
Study 38407394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 38407508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib (5, 10, 15, 20, 30, and 45 mg once daily)
Number of subjects: 72
Study 38407601 — intervention group
Group type: EXPERIMENTAL
Intervention: Zosuquidar (Zos) as a 72-h continuous intravenous infusion with chemotherapy (daunorubicin and cytarabine)
Number of subjects: 106
Study 38407601 — intervention group
Group type: EXPERIMENTAL
Intervention: Zosuquidar (Zos) as a 72-h continuous intravenous infusion
Number of subjects: 106
Study 38407610 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-1a immunised pregnancies
Number of subjects: 913
Study 38407610 — intervention group
Group type: COMPARATOR
Intervention: HPA-1a-negative pregnancies (non-immunised)
Number of subjects: 913
Study 38407610 — intervention group
Group type: COMPARATOR
Intervention: HPA-1a-positive pregnancies (randomly selected)
Number of subjects: 913
Study 38407630 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPSMA-10.1 and -10.2 radiolabeled with lutetium-177
Number of subjects: 0
Study 38407630 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPSMA-10.1 and -10.2
Number of subjects: 0
Study 38407674 — intervention group
Group type: EXPERIMENTAL
Intervention: 5xSTS (Five-time sit-to-stand test)
Number of subjects: 77
Study 38407674 — intervention group
Group type: EXPERIMENTAL
Intervention: HerQLes (Hernia-Related Quality-of-Life survey)
Number of subjects: 77
Study 38407674 — intervention group
Group type: EXPERIMENTAL
Intervention: QUeST (Quiet Unstable Sitting Test)
Number of subjects: 77
Study 38407697 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental Profile, 4th edition (DP-4) via telehealth
Number of subjects: 93
Study 38407697 — intervention group
Group type: COMPARATOR
Intervention: Mullen Scales of Early Learning (MSEL) in-person testing
Number of subjects: 93
Study 38407817 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic ARDS patients
Number of subjects: 214
Study 38407817 — intervention group
Group type: COMPARATOR
Intervention: Non-ARDS patients
Number of subjects: 214
Study 38407817 — intervention group
Group type: EXPERIMENTAL
Intervention: ARDS nonsurvivors
Number of subjects: 214
Study 38407848 — intervention group
Group type: EXPERIMENTAL
Intervention: Different interdialytic intervals
Number of subjects: 0
Study 38407859 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin milk 300 μg
Number of subjects: 198
Study 38407859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 38407859 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin milk 300 μg (2 to 11 years age group)
Number of subjects: 198
Study 38407859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 to 11 years age group)
Number of subjects: 198
Study 38407859 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin milk (all doses)
Number of subjects: 198
Study 38407859 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin milk 500 μg
Number of subjects: 198
Study 38407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ascites
Number of subjects: 131
Study 38407871 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotic patients without ascites
Number of subjects: 131
Study 38407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with portal vein thrombosis (PVT)
Number of subjects: 131
Study 38407871 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotic patients without portal vein thrombosis (PVT)
Number of subjects: 131
Study 38407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 131
Study 38407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of portal vein thrombosis (PVT)
Number of subjects: 131
Study 38407974 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAase (0.1%) eye drops four times daily for 8 weeks
Number of subjects: 58
Study 38407974 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) eye drops
Number of subjects: 58
Study 38408060 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 1800mg)
Number of subjects: 45
Study 38408060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (4.5mg)
Number of subjects: 45
Study 38408060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 38408067 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER mobile app with health coaching and shared decision-making interventions
Number of subjects: 0
Study 38408067 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (Control)
Number of subjects: 0
Study 38408215 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 911
Study 38408215 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (oral pre-exposure prophylaxis)
Number of subjects: 911
Study 38408215 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST and PrEP
Number of subjects: 911
Study 38408215 — intervention group
Group type: COMPARATOR
Intervention: HIVST-alone
Number of subjects: 911
Study 38408215 — intervention group
Group type: COMPARATOR
Intervention: PrEP-alone
Number of subjects: 911
Study 38408215 — intervention group
Group type: COMPARATOR
Intervention: PrEP and HIVST
Number of subjects: 911
Study 38408310 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality Pelli-Robson contrast sensitivity test
Number of subjects: 28
Study 38408310 — intervention group
Group type: COMPARATOR
Intervention: In-office Pelli-Robson contrast sensitivity test
Number of subjects: 28
Study 38408310 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality Pelli-Robson test
Number of subjects: 28
Study 38408310 — intervention group
Group type: COMPARATOR
Intervention: In-office test
Number of subjects: 28
Study 38408310 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality Pelli-Robson results
Number of subjects: 28
Study 38408357 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib+remdesivir
Number of subjects: 67
Study 38408357 — intervention group
Group type: COMPARATOR
Intervention: Placebo+remdesivir
Number of subjects: 67
Study 38408443 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Palmitoylethanolamide (Levagen+) applied twice daily for 4 weeks
Number of subjects: 72
Study 38408443 — intervention group
Group type: COMPARATOR
Intervention: Standard moisturiser (comparator) applied twice daily for 4 weeks
Number of subjects: 72
Study 38408457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (1 mg/kg, 3 mg/kg, 7 mg/kg, 12 mg/kg)
Number of subjects: 40
Study 38408457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (1 mg/kg)
Number of subjects: 40
Study 38408457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (3 mg/kg)
Number of subjects: 40
Study 38408457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (7 mg/kg)
Number of subjects: 40
Study 38408457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (12 mg/kg)
Number of subjects: 40
Study 38408457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38408457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody
Number of subjects: 40
Study 38408462 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced strategy group (internal champion plus external supervision with audit and feedback)
Number of subjects: 589
Study 38408462 — intervention group
Group type: COMPARATOR
Intervention: Basic strategy group (internal champion alone)
Number of subjects: 589
Study 38408702 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 658
Study 38408702 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 658
Study 38408725 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at early pregnancy
Number of subjects: 214
Study 38408725 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) at early pregnancy
Number of subjects: 214
Study 38408725 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 214
Study 38408725 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosatetraenoic acid (DTA)
Number of subjects: 214
Study 38408729 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of a beverage sweetened with 25% of the ADI of stevia for 4 weeks
Number of subjects: 59
Study 38408729 — intervention group
Group type: COMPARATOR
Intervention: Daily consumption of a beverage sweetened with 30 g of sucrose for 4 weeks
Number of subjects: 59
Study 38408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant measurement (CM)
Number of subjects: 3473
Study 38408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant small measurement (CsM)
Number of subjects: 3473
Study 38408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant smaller birth weight (sBW)
Number of subjects: 3473
Study 38408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant smaller head circumference (sHC)
Number of subjects: 3473
Study 38408943 — intervention group
Group type: EXPERIMENTAL
Intervention: Handsewn anastomoses (end-to-end or Kono-S)
Number of subjects: 354
Study 38408943 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis (side-to-side)
Number of subjects: 354
Study 38408999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilovertamab in combination with paclitaxel
Number of subjects: 16
Study 38409060 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination therapy
Number of subjects: 50
Study 38409060 — intervention group
Group type: COMPARATOR
Intervention: Upper limb motor therapy
Number of subjects: 50
Study 38409075 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Self-efficacy (PAS) intervention, an online behavioral intervention designed to promote physical activity.
Number of subjects: 30
Study 38409075 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control group).
Number of subjects: 30
Study 38409086 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 256
Study 38409086 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without POCUS)
Number of subjects: 256
Study 38409089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist delivered QuitAid intervention (yes)
Number of subjects: 24
Study 38409089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (NRT) gum + NRT patch
Number of subjects: 24
Study 38409089 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of NRT
Number of subjects: 24
Study 38409089 — intervention group
Group type: COMPARATOR
Intervention: Standard 4 weeks of NRT
Number of subjects: 24